We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Gmp3.0
Glycomacropeptide Research
Mostly mechanism / observationalHigh safety
12 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Glycomacropeptide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2008–2023 with a typical study size of 24 participants.
Based on 12 studies · 1 meta-analysis · 7 RCTs · 270 total participants
Confidence
Moderate
By outcome
Weight & appetiteMixed and often null — several acute RCTs found no effect of GMP itself on appetite, CCK, or food intake; a few found small reductions in next-meal energy intake. Not a reliable weight-loss tool on its own. · Acute (per-meal), if at all
Mostly mechanism / observational10 studies
PKU & phenylalanine control
Mostly mechanism / observational4 studies
Gut & microbiotaPlausible gut/anti-inflammatory and microbiota effects, but human digestive-outcome evidence is thin — mostly animal/in-vitro and a single small microbiome RCT. Treat as exploratory. · Weeks (uncertain)
Mostly mechanism / observational3 studies
Steady research
3 studies in the last 5 years · Latest meta-analysis: 2018
200820152023
1Meta-Analysis2018
A meta-analysis was performed with two studies with adequate comparable methodology which showed no differences between GMP-AAs and AAs for any of the interventions analysed.
Pena MJ, Pinto A, Daly A, MacDonald A, Azevedo L, Rocha JC, Borges N. · Nutrients (2018)
Systematic review of eight intervention studies of GMP-AA in PKU; meta-analysis of two methodologically comparable trials
No difference between GMP-AA and amino acids for blood phenylalanine control or other outcomes
All included studies were short-term with small sample sizes
GMP alone did not reduce subsequent food intake compared with a drink enriched with carbohydrate ... The presence of GMP in whey does not appear to be the cause of the observed effect of whey protein on satiety.
There was some evidence that whey proteins and their components enhance satiety over a short-term period compared to carbohydrate but there was no consistent effect of either whey protein alone or glycomacropeptide.
There was no indication to support a relationship between CGMP and satiety, as evidenced by decreased energy intake, thereby preventing overweight or obesity.
Daly A, Evans S, Pinto A, Jackson R, Ashmore C, Rocha JC, MacDonald A. · Nutrients (2020)
Three-year longitudinal prospective study in 48 children with PKU comparing amino acids vs two amounts of CGMP-AA
No differences in energy intake, weight, BMI, or incidence of overweight/obesity between groups
Found no evidence that GMP enhances satiety in this population
GMP as a whey-fraction reduced energy intake coinciding with increased concentrations of certain amino acids, irrespective of the concentration of whey-protein.
GMP alone is not critical in pre-meal whey-induced satiety; however, it may have a unique role in compensatory intake regulation managing daily energy intake.
Burton-Freeman BM. · Physiol Behav (2008)
Within-subjects RCT in 20 healthy-weight adults comparing whey, whey without GMP, low-protein control, and GMP isolate preloads
GMP alone was not critical to pre-meal whey-induced satiety
CCK patterns predicted satiety in women but not men; effects were sex-specific
CGMP had no systemic or intestinal immunomodulatory effects compared with a reference drink, with regard to either hsCRP or faecal calprotectin level, faecal microbiota composition or faecal SCFA content. CGMP ingestion did not affect satiety or body weight.